Preview: India's third largest pharmaceutical company, Cipla, is scheduled to deliver its October-December quarterly earnings ...

Cipla Limited is an India-based global pharmaceutical ... Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective ...

Mumbai: Cipla has announced that the United States Food and Drugs Administration (USFDA) has concluded an inspection at the ...

New Delhi: In line with the 'Not of Standard Quality' data provided by states, the apex drug regulatory body, the Central ...

Cipla has launched a mobile application, CipAir, to aid in asthma screening in India, aiming to address the country's high asthma burden and underdiagnosis. India's pharmaceutical industry is poised ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Cipla on Monday (January 20) announced that the United States Food and Drug Administration conducted an inspection of its ...

Cipla's product portfolio spans complex generics as well as drugs in the respiratory anti-retroviral urology cardiology anti-infective CNS and various other key therapeutic segments. With a rich ...

Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

India's drug regulator identifies 135 drugs as 'not of standard quality' in December, including popular medications.

There has been a lot of buzz over the regulation of dietary or nutritional supplements. But do you even need them?

Cipla's shares are currently priced at Rs 1439.65, reflecting a modest rise of 0.82%. The 7-day simple moving average is Rs 1475.93. Cipla is currently valued at Rs 1437.65, with a daily increase of 0 ...